Malignant pheochromocytoma and paraganglioma: Three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs

Acta Oncologica

Volumn 50, Issue 8, 2011, Pages 1255-1259

  Zukauskaite, Ruta ^a   Hjorthgau, Karin ^a   Poulsen, Per Logstrup ^a   Baerentzen, Steen ^a   Ladekarl, Morten ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CD56 ANTIGEN; CHROMOGRANIN A; CYCLOPHOSPHAMIDE; CYTOKERATIN AE1; CYTOKERATIN AE3; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; METADRENALIN; NORADRENALIN; NORADRENALIN TRANSPORTER; PENTETREOTIDE IN 111; PROTEIN S 100; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUNITINIB; SYNAPTOPHYSIN; TEMOZOLOMIDE; VINCRISTINE;

ADRENAL MEDULLA; ADRENALECTOMY; ANAMNESIS; BRAIN METASTASIS; CALVARIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CERVICAL LYMPH NODE; CHROMAFFIN SYSTEM; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DNA SEQUENCE; DRUG ERUPTION; DRUG WITHDRAWAL; DURA MATER; FATIGUE; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; ILEUS; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LAMINECTOMY; LETTER; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONVERBAL COMMUNICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RETROPERITONEUM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD COMPRESSION; SPINAL CORD TUMOR; SWEATING; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; ULTRASOUND; URINARY EXCRETION;

ADRENAL GLAND NEOPLASMS; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS;

EID: 80155195454     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.584552     Document Type: Letter

References (21)

1. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983;58:802-4.
2. Adjallé R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009;41:687-96.
3. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-85.
4. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, et al. Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006;1073:465-90.
5. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, et al. Pheochromocytoma: Current approaches and future directions. Oncologist 2008;13:779-93.
6. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. Lancet 2005;366(9486):665-75.
7. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, et al. Malignant pheochromocytoma: Current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-36.
8. Disick GI, Palese MA. Extra-adrenal pheochromocytoma: Diagnosis and management. Curr Urol Rep 2007;8:83-8.
9. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, et al. Survival of patients with metastatic malignant pheochromocytoma and effi cacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 2009;94:2850-6.
10. Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006;1073:374-82.
11. Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725-33.
12. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008;52:334-40.
13. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91.
14. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6.
15. Santarpia L, Habra MA, Jimé nez C. Malignant pheochromocytomas and paragangliomas: Molecular signaling pathways and emerging therapies. Horm Metab Res 2009;41: 680-6.
16. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/ pheochromocytoma. J Clin Endocrinol Metab 2009;94:5-9.
17. Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 2009;27:460-3.
18. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, et al. Sunitinib, a novel therapy for anthracycline- and cisplatinrefractory malignant pheochromocytoma. Jpn J Clin Oncol 2009;39:327-31.
19. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26: 3403-10.
20. Dimou AT, Syrigos KN, Saif MW. Neuroendocrine tumors of the pancreas: What's new haven highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, Florida, USA. January 22 - 24, 2010 JOP. J Pancreas [Internet] 2010 Mar 5;11:135-8.
21. Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Semin Oncol 2010;37:662-79.